Marinus Pharmaceuticals, Inc
MRNS
MRNS was delisted on the 10th of February, 2025.
112 hedge funds and large institutions have $486M invested in Marinus Pharmaceuticals, Inc in 2024 Q1 according to their latest regulatory filings, with 21 funds opening new positions, 38 increasing their positions, 36 reducing their positions, and 13 closing their positions.
62% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 13
7% more funds holding
Funds holding: 105 → 112 (+7)
6% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 36
17% less capital invested
Capital invested by funds: $585M → $486M (-$98.7M)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
45% less call options, than puts
Call options by funds: $14.8M | Put options by funds: $27M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
+$9.63M |
| 2 |
Balyasny Asset Management
Chicago,
Illinois
|
+$8.26M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$6.29M |
| 4 |
ABG
Ally Bridge Group
New York
|
+$3.84M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
+$3.76M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$21.2M |
| 2 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$6.13M |
| 3 |
SI
Sofinnova Investments
Menlo Park,
California
|
-$3.61M |
| 4 |
Franklin Resources
San Mateo,
California
|
-$3.31M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
-$2.43M |
MRNS Hedge Fund Activity: Q1 2024 in Review
112 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in Marinus Pharmaceuticals, Inc (MRNS) for Q1 2024, worth a combined $486M — down 17% from $585M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new MRNS positions and 13 closed out — a net gain of 8 holders — while 38 added to existing stakes and 36 trimmed.
The largest buyer was Avoro Capital Advisors, adding an estimated $9.63M. The largest seller was Eventide Asset Management, cutting an estimated $21.2M.
- 112 institutional investors held Marinus Pharmaceuticals, Inc (MRNS) as of Q1 2024, up from 105 in Q4 2023.
- Funds reported $486M of Marinus Pharmaceuticals, Inc stock for Q1 2024, down 17% quarter-over-quarter.
- 21 funds opened new Marinus Pharmaceuticals, Inc positions in Q1 2024 and 13 closed out, a net change of +8 holders.
- The largest Marinus Pharmaceuticals, Inc buyer in Q1 2024 was Avoro Capital Advisors, an estimated $9.63M added.
- The largest Marinus Pharmaceuticals, Inc seller in Q1 2024 was Eventide Asset Management, an estimated $21.2M sold.
Based on aggregated 13F filings for Q1 2024.